Cargando…

Tumor-derived biomimetic nanozyme with immune evasion ability for synergistically enhanced low dose radiotherapy

High doses of radiation can cause serious side effects and efficient radiosensitizers are urgently needed. To overcome this problem, we developed a biomimetic nanozyme system (CF) by coating pyrite (FeS(2)) into tumor-derived exosomes for enhanced low-dose radiotherapy (RT). CF system give FeS(2) wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Chunyu, Liu, Zeming, Chen, Mingzhu, Du, Liang, Liu, Chunping, Wang, Shuntao, Zheng, Yongfa, Liu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715603/
https://www.ncbi.nlm.nih.gov/pubmed/34963466
http://dx.doi.org/10.1186/s12951-021-01182-y
_version_ 1784624159586779136
author Huang, Chunyu
Liu, Zeming
Chen, Mingzhu
Du, Liang
Liu, Chunping
Wang, Shuntao
Zheng, Yongfa
Liu, Wei
author_facet Huang, Chunyu
Liu, Zeming
Chen, Mingzhu
Du, Liang
Liu, Chunping
Wang, Shuntao
Zheng, Yongfa
Liu, Wei
author_sort Huang, Chunyu
collection PubMed
description High doses of radiation can cause serious side effects and efficient radiosensitizers are urgently needed. To overcome this problem, we developed a biomimetic nanozyme system (CF) by coating pyrite (FeS(2)) into tumor-derived exosomes for enhanced low-dose radiotherapy (RT). CF system give FeS(2) with immune escape and homologous targeting abilities. After administration, CF with both glutathione oxidase (GSH-OXD) and peroxidase (POD) activities can significantly lower the content of GSH in tumor tissues and catalyze intracellular hydrogen peroxide (H(2)O(2)) to produce a large amount of ·OH for intracellular redox homeostasis disruption and mitochondria destruction, thus reducing RT resistance. Experiments in vivo and in vitro showed that combining CF with RT (2 Gy) can provide a substantial suppression of tumor proliferation. This is the first attempt to use exosomes bionic FeS(2) nanozyme for realizing low-dose RT, which broaden the prospects of nanozymes. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-01182-y.
format Online
Article
Text
id pubmed-8715603
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87156032022-01-05 Tumor-derived biomimetic nanozyme with immune evasion ability for synergistically enhanced low dose radiotherapy Huang, Chunyu Liu, Zeming Chen, Mingzhu Du, Liang Liu, Chunping Wang, Shuntao Zheng, Yongfa Liu, Wei J Nanobiotechnology Research High doses of radiation can cause serious side effects and efficient radiosensitizers are urgently needed. To overcome this problem, we developed a biomimetic nanozyme system (CF) by coating pyrite (FeS(2)) into tumor-derived exosomes for enhanced low-dose radiotherapy (RT). CF system give FeS(2) with immune escape and homologous targeting abilities. After administration, CF with both glutathione oxidase (GSH-OXD) and peroxidase (POD) activities can significantly lower the content of GSH in tumor tissues and catalyze intracellular hydrogen peroxide (H(2)O(2)) to produce a large amount of ·OH for intracellular redox homeostasis disruption and mitochondria destruction, thus reducing RT resistance. Experiments in vivo and in vitro showed that combining CF with RT (2 Gy) can provide a substantial suppression of tumor proliferation. This is the first attempt to use exosomes bionic FeS(2) nanozyme for realizing low-dose RT, which broaden the prospects of nanozymes. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-01182-y. BioMed Central 2021-12-28 /pmc/articles/PMC8715603/ /pubmed/34963466 http://dx.doi.org/10.1186/s12951-021-01182-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Huang, Chunyu
Liu, Zeming
Chen, Mingzhu
Du, Liang
Liu, Chunping
Wang, Shuntao
Zheng, Yongfa
Liu, Wei
Tumor-derived biomimetic nanozyme with immune evasion ability for synergistically enhanced low dose radiotherapy
title Tumor-derived biomimetic nanozyme with immune evasion ability for synergistically enhanced low dose radiotherapy
title_full Tumor-derived biomimetic nanozyme with immune evasion ability for synergistically enhanced low dose radiotherapy
title_fullStr Tumor-derived biomimetic nanozyme with immune evasion ability for synergistically enhanced low dose radiotherapy
title_full_unstemmed Tumor-derived biomimetic nanozyme with immune evasion ability for synergistically enhanced low dose radiotherapy
title_short Tumor-derived biomimetic nanozyme with immune evasion ability for synergistically enhanced low dose radiotherapy
title_sort tumor-derived biomimetic nanozyme with immune evasion ability for synergistically enhanced low dose radiotherapy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715603/
https://www.ncbi.nlm.nih.gov/pubmed/34963466
http://dx.doi.org/10.1186/s12951-021-01182-y
work_keys_str_mv AT huangchunyu tumorderivedbiomimeticnanozymewithimmuneevasionabilityforsynergisticallyenhancedlowdoseradiotherapy
AT liuzeming tumorderivedbiomimeticnanozymewithimmuneevasionabilityforsynergisticallyenhancedlowdoseradiotherapy
AT chenmingzhu tumorderivedbiomimeticnanozymewithimmuneevasionabilityforsynergisticallyenhancedlowdoseradiotherapy
AT duliang tumorderivedbiomimeticnanozymewithimmuneevasionabilityforsynergisticallyenhancedlowdoseradiotherapy
AT liuchunping tumorderivedbiomimeticnanozymewithimmuneevasionabilityforsynergisticallyenhancedlowdoseradiotherapy
AT wangshuntao tumorderivedbiomimeticnanozymewithimmuneevasionabilityforsynergisticallyenhancedlowdoseradiotherapy
AT zhengyongfa tumorderivedbiomimeticnanozymewithimmuneevasionabilityforsynergisticallyenhancedlowdoseradiotherapy
AT liuwei tumorderivedbiomimeticnanozymewithimmuneevasionabilityforsynergisticallyenhancedlowdoseradiotherapy